The Taipei Times reported that Sanofi has agreed to recall a batch of heart disease drug Tritace due to possible contamination, according to Taiwan's Food and Drug Administration.
The agency said it had received a report about suspected contamination in Tritace as dark spots were found on some tablets.
A preliminary investigation suggests that the dark spots might be dried human blood from workers who might have had small wounds on their hands and wore broken gloves while operating machines during the manufacturing process, the company said.
Tritace is mainly used to treat hypertension and post-myocardial infarction heart failure, as well as to prevent cardiovascular disease in people who are at greater risk, the agency added.
To read more NewsPoints articles, click here.